Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis

Shailendra Singh, Ahmad Najdat Bazarbashi, Ahmad Khan, Monica Chowdhry, Mohammad Bilal, Diogo Turiani Hourneaux de Moura, Pichamol Jirapinyo, Shyam Thakkar, Christopher C. Thompson

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Primary obesity surgery endoluminal (POSE) utilizes an incision-less operating platform system to create full-thickness plications in the gastric fundus and body (original POSE). Many studies have demonstrated the safety and efficacy of original POSE for the treatment of obesity. Objective: We aimed to conduct a systematic review and meta-analysis of available literature in an attempt to evaluate the outcomes of original POSE per the ASGE task force thresholds. Methods: Bibliographic databases were systematically searched for studies assessing the outcomes of POSE for the treatment of obesity. All randomized controlled trials (RCTs) and observational studies that assessed outcomes of POSE were included. Studies were included if they reported percent total weight loss (%TWL) or percent excess weight loss (%EWL) and the incidence of serious adverse events (SAE). Results: A total of seven studies with 613 patients were included. Two included studies were RCTs, while the remaining were observational studies. Pooled mean %EWL at 3–6 months and 12–15 months were 42.62 (95% CI 37.56–47.68) and 48.86 (95% CI 42.31–55.41), respectively. Pooled mean %TWL at 3–6 months and 12–15 months was 13.45 (95% CI 8.93–17.97) and 12.68 (95% CI 8.13–17.23), respectively. Subgroup analysis of two RCTs showed that weight loss at 1 year was significantly higher in POSE patients (%EWL difference in means 19.45 (95% CI 4.65–34.24, p value = 0.01). The overall incidence of serious adverse events was only 2.84% and included GI bleeding, extra-gastric bleeding, hepatic abscess, severe pain, severe nausea, and severe vomiting. The mean number of total anchors placed in the fundus and body was 13.18 (95% CI 11.77–14.58), and the mean procedure time was 44.55 min (95% CI 36.44–52.65). Conclusion: POSE, a minimally invasive endoscopic bariatric therapy, is a safe and effective modality for the treatment of obesity. The outcomes of POSE meet and surpass the ASGE joint task force thresholds. Future studies should evaluate newer versions of this procedure that emphasize gastric body plication sparing the fundus.

Original languageEnglish
Pages (from-to)252-266
Number of pages15
JournalSurgical endoscopy
Volume36
Issue number1
DOIs
StatePublished - Jan 2022

Keywords

  • EBMTs
  • Endoscopic bariatric and metabolic therapies
  • Endoscopic bariatric therapy
  • Endoscopic gastroplasty
  • POSE
  • Primary obesity surgery endoluminal
  • Weight loss

Fingerprint

Dive into the research topics of 'Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this